LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)

被引：6
|
作者：
Salama, Vivian [1 ]
Brooks, Nathan [2 ]
Skwarska, Anna [1 ]
Kays, Lisa [2 ]
Milligan, Paul [3 ]
Newell, Katherine [4 ]
Roth, Kenneth [3 ]
Geeganage, Sandaruwan [2 ]
Gilmour, Raymond [2 ]
Chan, Steven M. [5 ]
Sarry, Jean-Emmanuel [6 ]
Sabatier, Mary [6 ]
DiNardo, Courtney [1 ]
Konopleva, Marina [1 ]
机构：
[1] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Lilly Res Labs, Discovery Oncol, Indianapolis, IN USA
[3] Lilly Res Labs, Discovery Chem & Res Technol, Indianapolis, IN USA
[4] Cognet LLC, Indianapolis, IN USA
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Univ Toulouse, INSERM, Canc Res Ctr Toulouse, Toulouse, France
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6417
引用
收藏
页数：2
相关论文
共 21 条
  • [1] Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)
    Brooks, Nathan
    DeWalt, Robin
    Boulet, Serge
    Lu, ZhaoHai
    Kays, Lisa
    Cavitt, Rachel
    Gomez, Sandra
    Strelow, John
    Milligan, Paul
    Roth, Kenneth
    Bauer, Renato
    Antonysamy, Stephen
    Hahn, Patric
    Rankovic, Zoran
    McCann, Denis
    Mo, Gary
    Tiu, Ramon
    Burkholder, Timothy
    Geeganage, Sandaruwan
    Gilmour, Raymond
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
    Gupta, Charu
    Kaulfuss, Stefan
    Goerlich, Kerstin
    Othman, Basem
    Chaturvedi, Anuhar
    Heuser, Michael
    ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1415 - 1417
  • [3] Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
    Charu Gupta
    Stefan Kaulfuss
    Kerstin Görlich
    Basem Othman
    Anuhar Chaturvedi
    Michael Heuser
    Annals of Hematology, 2020, 99 : 1415 - 1417
  • [4] Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
    Chaturvedi, Anuhar
    Gupta, Charu
    Gabdoulline, Razif
    Borchert, Nora M.
    Goparaju, Ramya
    Kaulfuss, Stefan
    Goerlich, Kerstin
    Schottmann, Renate
    Othman, Basem
    Welzenbach, Julia
    Panknin, Olaf
    Wagner, Markus
    Geffers, Robert
    Ganser, Arnold
    Thol, Felicitas
    Haegebarth, Andrea
    Jeffers, Michael
    Heuser, Michael
    HAEMATOLOGICA, 2021, 106 (02) : 565 - 573
  • [5] Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia
    Chaturvedi, Anuhar
    Gupta, Charu
    Goparaju, Ramya
    Gabdoulline, Razif
    Kaulfuss, Stefan
    Gorlich, Kerstin
    Schottmann, Renate
    Panknin, Olaf
    Wagner, Markus
    Geffers, Robert
    Ganser, Arnold
    Thol, Felicitas
    Jeffers, Michael
    Haegebarth, Andrea
    Heuser, Michael
    BLOOD, 2017, 130
  • [6] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Doehner, Hartmut
    Martinelli, Giovanni
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du
    Wang, Xiwei
    Gong, Jing
    Kapsalis, Stephanie M.
    Hickman, Denice
    Zhang, Vickie
    Winkler, Thomas
    Daigle, Scott
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
  • [7] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, C.
    Stein, A.
    Stein, E.
    Fathi, A.
    Frankfurt, O.
    Schuh, A.
    Doehner, H.
    Martinelli, G.
    Patel, P.
    Raffoux, E.
    Tan, P.
    Zeidan, A.
    de Botton, S.
    Kantarjian, H.
    Stone, R.
    Lam, D.
    Wang, X.
    Gong, J.
    Kapsalis, S.
    Hickman, D.
    Zhang, V.
    Winkler, T.
    Wu, B.
    Vyas, P.
    ANNALS OF HEMATOLOGY, 2019, 98 : S40 - S41
  • [9] Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia
    Cortes, Jorge E.
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (06) : 211 - 221
  • [10] Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
    A Chaturvedi
    L Herbst
    S Pusch
    L Klett
    R Goparaju
    D Stichel
    S Kaulfuss
    O Panknin
    K Zimmermann
    L Toschi
    R Neuhaus
    A Haegebarth
    H Rehwinkel
    H Hess-Stumpp
    M Bauser
    T Bochtler
    E A Struys
    A Sharma
    A Bakkali
    R Geffers
    M M Araujo-Cruz
    F Thol
    R Gabdoulline
    A Ganser
    A D Ho
    A von Deimling
    K Rippe
    M Heuser
    A Krämer
    Leukemia, 2017, 31 : 2020 - 2028
123